✦ LIBER ✦

Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

✍ Scribed by Bo Guo; Hong-Li Zhu; Hui Fan; Su-Xia Li; Xue-Chun Lu; Jie Lin; Hai-Hong Ran; Bing Zhai; Yang Yang

Book ID: 107648821
Publisher: Springer Healthcare Communications
Year: 2012
Tongue: English
Weight: 714 KB
Volume: 29
Category: Article
ISSN: 0741-238X
DOI: 10.1007/s12325-011-0097-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral fludarabine in untreated patients w

Oral fludarabine in untreated patients with B-cell chronic lymphocytic leukemia

✍ Shustik, C; Turner, A R; Desjardins, P; Fernandez, L; Rubin, S; Larratt, L; Dunc 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 194 KB

Fludarabine in patients with advanced an

Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia

✍ P. L. Zinzani; F. Lauria; D. Rondelli; D. Benfenati; D. Raspadori; M. Bocchia; A 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

3.16 Increased Incidence of Chronic Lymp

3.16 Increased Incidence of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Patients with Merkel Cell Carcinoma in Israel

✍ Tamar Tadmor; Irena Liphshitz; Ariel Aviv; Ola Landgren; Micha Barchana; Aaron P 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 93 KB

A phase I/II study of rituximab and etan

A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma

✍ Lin, T S; Lucas, M S; Heerema, N; Moran, M E; Cheney, C; Woyach, J A; Lucas, D M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 160 KB

Amifostine does not reduce the toxicity

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

✍ Francis J. Giles; Gary Guangping Shi; Jorge E. Cortes; Deborah Thomas; Anna R. K 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 189 KB

Pentostatin, cyclophosphamide, and ritux

Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia

✍ Tait D. Shanafelt; Thomas Lin; Susan M. Geyer; Clive S. Zent; Nelson Leung; Bria 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## BACKGROUND. The prevalence of chronic lymphocytic leukemia (CLL) increases with age. Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients ≥70 years of age. ## METHODS. Sixty‐four